TABLE 3.
Changing antimicrobial resistance by different age groups between 2012 and 2019.
| AGE | <1 Y | 1–2 Y | 2–5 Y | >5 Y | P value |
| 2012 | |||||
| MDR | 12.1%(12/99) | 11.6%(18/155) | 14.9%(14/94) | 0%(0/15) | 0.426 |
| Ampicillin | 48.5%(48/99) | 54.2%(84/155) | 42.3%(22/52) | 43.1%(25/58) | 0.279 |
| Ceftriaxone | 3%(3/99) | 5.2%(8/155) | 4.3%(4/94) | 0%(0/15) | 0.575 |
| Ciprofloxacin | 2%(2/99) | 1.9%(3/155) | 2.1%(2/94) | 0%(0/15) | 0.895 |
| TMP-SMX | 25.3%(25/99) | 25.8%(40/155) | 34%(32/94) | 13.3%(2/15) | 0.260 |
| Ertapenem | 0%(0/99) | 0%(0/155) | 0%(0/94) | 0%(0/15) | |
| Imipenem | 0%(0/99) | 0%(0/155) | 0%(0/94) | 0%(0/15) | |
| Chloramphenicol | 28.3%(28/99) | 22.6%(35/155) | 16%(15/94) | 6.7%(1/15) | 0.094 |
| Flomoxef | 4%(4/99) | 2.6%(4/155) | 4.3%(4/94) | 0%(0/15) | 0.641 |
| 2019 | |||||
| MDR | 42.5%(37/87) | 22.2%(40/180) | 29.6%(37/125) | 38.1%(16/42) | 0.005 |
| Ampicillin | 50.6%(44/87) | 32.8%(59/180) | 41.6%(52/125) | 19.0%(8/42) | 0.036 |
| Ceftriaxone | 25.3%(22/87) | 8.3%(15/180) | 13.6%(17/125) | 19.0%(8/42) | 0.002 |
| Ciprofloxacin | 34.9%(30/86) | 23.9%(43/180) | 28.8%(36/125) | 35.7%(15/42) | 0.199 |
| TMP-SMX | 44.2%(38/86) | 22.3%(40/179) | 26.4%(33/125) | 38.1%(16/42) | 0.001 |
| Ertapenem | 2.3%(2/87) | 0.6%(1/180) | 0%(0/125) | 0%(0/42) | 0.221 |
| Imipenem | 3.4%(3/87) | 0.6%(1/180) | 0%(0/125) | 2.4%(1/42) | 0.084 |
| Chloramphenicol | 46.3%(37/80) | 24.4%(39/160) | 27.9(34/122) | 39%(16/41) | 0.003 |
| Flomoxef | 3.8%(3/80) | 4.4%(7/160) | 8.2%(10/122) | 49.8%(4/41) | 0.326 |
MDR, multi-drug resistance, resistant to ≥3 drug classes.